Generic Rayos Availability

Rayos is a brand name of prednisone, approved by the FDA in the following formulation(s):

RAYOS (prednisone - tablet, delayed release;oral)

  • Manufacturer: HORIZON PHARMA
    Approval date: July 26, 2012
    Strength(s): 1MG, 2MG, 5MG [RLD]

Has a generic version of Rayos been approved?

No. There is currently no therapeutically equivalent version of Rayos available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rayos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Corticosteroid formulation
    Patent 6,488,960
    Issued: December 3, 2002
    Inventor(s): Hazel Judith; Bardsley
    Assignee(s): Arakis Ltd.
    The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.
    Patent expiration dates:
    • March 14, 2020
      ✓ 
      Patent use: TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
      ✓ 
      Drug product
  • Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
    Patent 6,677,326
    Issued: January 13, 2004
    Inventor(s): Hazel Judith; Bardsley & Robin Mark; Bannister & Julian Clive; Gilbert
    Assignee(s): Arakis, Ltd.
    The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.
    Patent expiration dates:
    • March 14, 2020
      ✓ 
      Patent use: TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
      ✓ 
      Drug product
  • Delayed release tablet with defined core geometry
    Patent 8,168,218
    Issued: May 1, 2012
    Inventor(s): Vergnault; Guy & Grenier; Pascal & Dragan; Christophe
    Assignee(s): Jagotec AG
    A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker than the coating about the axis A-B, and is adapted to provide a lag time of between about 2 to 6 hours during which substantially no drug substance is released.
    Patent expiration dates:
    • January 7, 2028
      ✓ 
      Patent use: TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
      ✓ 
      Drug product
  • Delayed release tablet with defined core geometry
    Patent 8,309,124
    Issued: November 13, 2012
    Inventor(s): Vergnault; Guy & Grenier; Pascal & Dragan; Christophe
    Assignee(s): Jagotec AG
    A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Patent expiration dates:
    • April 23, 2024
      ✓ 
      Patent use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
    • April 23, 2024
  • Delayed release tablet with defined core geometry
    Patent 8,394,407
    Issued: March 12, 2013
    Assignee(s): Jagotec AG
    A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Patent expiration dates:
    • April 23, 2024
      ✓ 
      Patent use: TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 26, 2015 - CLINICAL TRIAL STUDY RESULTS

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)